Blood Disorders & Hematology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

This Phase 3 trial is testing a new CAR-T cell therapy called anitocabtagene autoleucel as a possible alternative to the standard stem cell transplant for people newly diagnosed with multiple myeloma. If successful, this treatment could change the current approach to managing this blood cancer by offering a different option that might work better or have fewer side effects. The study plans to enroll 750 participants but is not yet recruiting.

A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

This Phase 3 trial is exploring if a new drug combination including Ramantamig and Daratumumab can improve outcomes for adults with newly diagnosed multiple myeloma who are eligible for stem cell transplant. It compares this new approach to the current standard treatment followed by transplant and maintenance therapy. The trial aims to enroll 1000 participants and is not yet recruiting.

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This Phase 2 trial is testing new combinations of drugs including tazemetostat and zanubrutinib alongside tafasitamab and lenalidomide for patients whose large B-cell lymphoma has come back or did not respond to previous treatments. The goal is to find better ways to shrink the cancer or delay its return, potentially offering new hope for patients with limited treatment choices. The study is currently recruiting in the United States and plans to enroll 227 participants.

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

This Phase 2 trial is looking at whether adding venetoclax to the usual Bruton Tyrosine Kinase Inhibitor treatment can improve results for veterans living with chronic lymphocytic leukemia or small lymphocytic lymphoma. Success could mean better response rates and the possibility of stopping therapy after one year, reducing long-term treatment burden. The study is recruiting in the United States and plans to enroll 100 participants.

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

This Phase 2 study tested a combination of brentuximab vedotin and nivolumab in patients with early stage classic Hodgkin lymphoma. The treatment approach aims to reduce the need for radiation therapy, potentially lessening side effects while improving outcomes through targeted immunotherapy. The trial has completed enrollment and results are now available from multiple sites in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.